Clinical Trial Update: Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence trial compared two nitisinone formulations to Orfadin for hereditary tyrosinemia type I; the study is completed and results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Tyrosinemia Type

Drugs mentioned

• Nitisinone formulation 1 (nitisinone)
• Nitisinone formulation 2 (nitisinone)
• Orfadin (nitisinone)

Snippet

Sponsor: Cycle Pharmaceuticals Ltd. | Conditions: Hereditary Tyrosinemia, Type I | Phase 1 | Status: COMPLETED | Results posted: 2016-12-13